Anaplastic oligodendrogliomas: Prognostic factors for tumor recurrence and survival

Vinay K. Puduvalli, Masood Hashmi, Leslie D. McAllister, Victor A. Levin, Kenneth R. Hess, Michael Prados, Kurt Jaeckle, W. K Alfred Yung, Saundra S. Buys, Janet M. Bruner, Jeannette J. Townsend, Richard Davis, Raymond Sawaya, Athanassios P. Kyritsis

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Objectives: Anaplastic oligodendrogliomas (AO) are uncommon primary brain tumors whose natural history, prognosis, and optimal management are not yet fully understood. However, they are associated with a better prognosis and response to multimodality therapy based on specific molecular changes. In this multicenter retrospective study, we analyzed the clinical characteristics of patients with AO to identify prognostic factors that influence time to progression (TTP) and survival. Methods: A retrospective search of the brain tumor databases of three institutions (the University of Texas M. D. Anderson Cancer Center, the University of California at San Francisco, and the University of Utah) for patients between 1977 and 1995 with histologically confirmed AO identified a cohort of 106 patients that was further analyzed in this study. Initial treatment included surgery alone (n = 12) or surgery followed by one of the following: radiotherapy (RT) alone (n = 49), chemotherapy alone (n = 4), chemotherapy followed by RT (n = 10), RT followed by chemotherapy (n = 20), and others (n = 11). Results: The median age at diagnosis was 43 years, and the median Karnofsky performance score (KPS) was 90. The overall median survival was 7.3 years, and the 5-year survival rate was 62%. Univariate analysis of several clinical variables showed that only age (p < 0.0001) and KPS (p = 0.04) correlated significantly with survival. Fifty patients had disease progression after initial therapy. The median TTP was 48 months. Age at diagnosis was the only variable that correlated significantly with TTP. Conclusions: A trend towards longer survival with a greater extent of resection was evident. The relative efficacy of various treatment modalities could not be definitively determined because of the heterogeneity of the therapies used. Overall, patients with AO have a better prognosis after therapy compared with those who have other malignant gliomas.

Original languageEnglish (US)
Pages (from-to)259-266
Number of pages8
JournalOncology
Volume65
Issue number3
DOIs
StatePublished - Dec 17 2003

Fingerprint

Oligodendroglioma
Recurrence
Survival
Radiotherapy
Neoplasms
Drug Therapy
Brain Neoplasms
Therapeutics
San Francisco
Natural History
Glioma
Multicenter Studies
Disease Progression
Survival Rate
Retrospective Studies
Databases

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Puduvalli, V. K., Hashmi, M., McAllister, L. D., Levin, V. A., Hess, K. R., Prados, M., ... Kyritsis, A. P. (2003). Anaplastic oligodendrogliomas: Prognostic factors for tumor recurrence and survival. Oncology, 65(3), 259-266. https://doi.org/10.1159/000074479
Puduvalli, Vinay K. ; Hashmi, Masood ; McAllister, Leslie D. ; Levin, Victor A. ; Hess, Kenneth R. ; Prados, Michael ; Jaeckle, Kurt ; Yung, W. K Alfred ; Buys, Saundra S. ; Bruner, Janet M. ; Townsend, Jeannette J. ; Davis, Richard ; Sawaya, Raymond ; Kyritsis, Athanassios P. / Anaplastic oligodendrogliomas : Prognostic factors for tumor recurrence and survival. In: Oncology. 2003 ; Vol. 65, No. 3. pp. 259-266.
@article{dabc01cd07a748f8bcdd5cc926d26e8c,
title = "Anaplastic oligodendrogliomas: Prognostic factors for tumor recurrence and survival",
abstract = "Objectives: Anaplastic oligodendrogliomas (AO) are uncommon primary brain tumors whose natural history, prognosis, and optimal management are not yet fully understood. However, they are associated with a better prognosis and response to multimodality therapy based on specific molecular changes. In this multicenter retrospective study, we analyzed the clinical characteristics of patients with AO to identify prognostic factors that influence time to progression (TTP) and survival. Methods: A retrospective search of the brain tumor databases of three institutions (the University of Texas M. D. Anderson Cancer Center, the University of California at San Francisco, and the University of Utah) for patients between 1977 and 1995 with histologically confirmed AO identified a cohort of 106 patients that was further analyzed in this study. Initial treatment included surgery alone (n = 12) or surgery followed by one of the following: radiotherapy (RT) alone (n = 49), chemotherapy alone (n = 4), chemotherapy followed by RT (n = 10), RT followed by chemotherapy (n = 20), and others (n = 11). Results: The median age at diagnosis was 43 years, and the median Karnofsky performance score (KPS) was 90. The overall median survival was 7.3 years, and the 5-year survival rate was 62{\%}. Univariate analysis of several clinical variables showed that only age (p < 0.0001) and KPS (p = 0.04) correlated significantly with survival. Fifty patients had disease progression after initial therapy. The median TTP was 48 months. Age at diagnosis was the only variable that correlated significantly with TTP. Conclusions: A trend towards longer survival with a greater extent of resection was evident. The relative efficacy of various treatment modalities could not be definitively determined because of the heterogeneity of the therapies used. Overall, patients with AO have a better prognosis after therapy compared with those who have other malignant gliomas.",
author = "Puduvalli, {Vinay K.} and Masood Hashmi and McAllister, {Leslie D.} and Levin, {Victor A.} and Hess, {Kenneth R.} and Michael Prados and Kurt Jaeckle and Yung, {W. K Alfred} and Buys, {Saundra S.} and Bruner, {Janet M.} and Townsend, {Jeannette J.} and Richard Davis and Raymond Sawaya and Kyritsis, {Athanassios P.}",
year = "2003",
month = "12",
day = "17",
doi = "10.1159/000074479",
language = "English (US)",
volume = "65",
pages = "259--266",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "3",

}

Puduvalli, VK, Hashmi, M, McAllister, LD, Levin, VA, Hess, KR, Prados, M, Jaeckle, K, Yung, WKA, Buys, SS, Bruner, JM, Townsend, JJ, Davis, R, Sawaya, R & Kyritsis, AP 2003, 'Anaplastic oligodendrogliomas: Prognostic factors for tumor recurrence and survival', Oncology, vol. 65, no. 3, pp. 259-266. https://doi.org/10.1159/000074479

Anaplastic oligodendrogliomas : Prognostic factors for tumor recurrence and survival. / Puduvalli, Vinay K.; Hashmi, Masood; McAllister, Leslie D.; Levin, Victor A.; Hess, Kenneth R.; Prados, Michael; Jaeckle, Kurt; Yung, W. K Alfred; Buys, Saundra S.; Bruner, Janet M.; Townsend, Jeannette J.; Davis, Richard; Sawaya, Raymond; Kyritsis, Athanassios P.

In: Oncology, Vol. 65, No. 3, 17.12.2003, p. 259-266.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anaplastic oligodendrogliomas

T2 - Prognostic factors for tumor recurrence and survival

AU - Puduvalli, Vinay K.

AU - Hashmi, Masood

AU - McAllister, Leslie D.

AU - Levin, Victor A.

AU - Hess, Kenneth R.

AU - Prados, Michael

AU - Jaeckle, Kurt

AU - Yung, W. K Alfred

AU - Buys, Saundra S.

AU - Bruner, Janet M.

AU - Townsend, Jeannette J.

AU - Davis, Richard

AU - Sawaya, Raymond

AU - Kyritsis, Athanassios P.

PY - 2003/12/17

Y1 - 2003/12/17

N2 - Objectives: Anaplastic oligodendrogliomas (AO) are uncommon primary brain tumors whose natural history, prognosis, and optimal management are not yet fully understood. However, they are associated with a better prognosis and response to multimodality therapy based on specific molecular changes. In this multicenter retrospective study, we analyzed the clinical characteristics of patients with AO to identify prognostic factors that influence time to progression (TTP) and survival. Methods: A retrospective search of the brain tumor databases of three institutions (the University of Texas M. D. Anderson Cancer Center, the University of California at San Francisco, and the University of Utah) for patients between 1977 and 1995 with histologically confirmed AO identified a cohort of 106 patients that was further analyzed in this study. Initial treatment included surgery alone (n = 12) or surgery followed by one of the following: radiotherapy (RT) alone (n = 49), chemotherapy alone (n = 4), chemotherapy followed by RT (n = 10), RT followed by chemotherapy (n = 20), and others (n = 11). Results: The median age at diagnosis was 43 years, and the median Karnofsky performance score (KPS) was 90. The overall median survival was 7.3 years, and the 5-year survival rate was 62%. Univariate analysis of several clinical variables showed that only age (p < 0.0001) and KPS (p = 0.04) correlated significantly with survival. Fifty patients had disease progression after initial therapy. The median TTP was 48 months. Age at diagnosis was the only variable that correlated significantly with TTP. Conclusions: A trend towards longer survival with a greater extent of resection was evident. The relative efficacy of various treatment modalities could not be definitively determined because of the heterogeneity of the therapies used. Overall, patients with AO have a better prognosis after therapy compared with those who have other malignant gliomas.

AB - Objectives: Anaplastic oligodendrogliomas (AO) are uncommon primary brain tumors whose natural history, prognosis, and optimal management are not yet fully understood. However, they are associated with a better prognosis and response to multimodality therapy based on specific molecular changes. In this multicenter retrospective study, we analyzed the clinical characteristics of patients with AO to identify prognostic factors that influence time to progression (TTP) and survival. Methods: A retrospective search of the brain tumor databases of three institutions (the University of Texas M. D. Anderson Cancer Center, the University of California at San Francisco, and the University of Utah) for patients between 1977 and 1995 with histologically confirmed AO identified a cohort of 106 patients that was further analyzed in this study. Initial treatment included surgery alone (n = 12) or surgery followed by one of the following: radiotherapy (RT) alone (n = 49), chemotherapy alone (n = 4), chemotherapy followed by RT (n = 10), RT followed by chemotherapy (n = 20), and others (n = 11). Results: The median age at diagnosis was 43 years, and the median Karnofsky performance score (KPS) was 90. The overall median survival was 7.3 years, and the 5-year survival rate was 62%. Univariate analysis of several clinical variables showed that only age (p < 0.0001) and KPS (p = 0.04) correlated significantly with survival. Fifty patients had disease progression after initial therapy. The median TTP was 48 months. Age at diagnosis was the only variable that correlated significantly with TTP. Conclusions: A trend towards longer survival with a greater extent of resection was evident. The relative efficacy of various treatment modalities could not be definitively determined because of the heterogeneity of the therapies used. Overall, patients with AO have a better prognosis after therapy compared with those who have other malignant gliomas.

UR - http://www.scopus.com/inward/record.url?scp=0344737846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344737846&partnerID=8YFLogxK

U2 - 10.1159/000074479

DO - 10.1159/000074479

M3 - Article

C2 - 14657600

AN - SCOPUS:0344737846

VL - 65

SP - 259

EP - 266

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -

Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M et al. Anaplastic oligodendrogliomas: Prognostic factors for tumor recurrence and survival. Oncology. 2003 Dec 17;65(3):259-266. https://doi.org/10.1159/000074479